| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,552 |
3,950 |
$555K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,282 |
1,934 |
$536K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,580 |
5,796 |
$506K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
2,207 |
1,956 |
$151K |
| 80053 |
Comprehensive metabolic panel |
10,560 |
9,013 |
$68K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
606 |
533 |
$57K |
| 84443 |
Thyroid stimulating hormone (TSH) |
4,537 |
4,175 |
$48K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,075 |
9,164 |
$47K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,030 |
923 |
$46K |
| 80061 |
Lipid panel |
4,462 |
4,140 |
$42K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,546 |
415 |
$37K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,110 |
833 |
$35K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
794 |
635 |
$32K |
| 70450 |
Computed tomography, head or brain; without contrast material |
577 |
517 |
$24K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,132 |
1,056 |
$22K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,011 |
2,795 |
$20K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
321 |
293 |
$19K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,882 |
1,608 |
$19K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
421 |
345 |
$15K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
243 |
211 |
$14K |
| 71045 |
Radiologic examination, chest; single view |
2,611 |
2,229 |
$13K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
700 |
653 |
$12K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,734 |
1,357 |
$11K |
| 84484 |
|
2,304 |
1,784 |
$10K |
| 71046 |
Radiologic examination, chest; 2 views |
1,032 |
941 |
$9K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,419 |
2,005 |
$9K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
46 |
35 |
$9K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
862 |
776 |
$8K |
| 36415 |
Collection of venous blood by venipuncture |
7,250 |
5,681 |
$8K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,779 |
1,409 |
$8K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
965 |
870 |
$7K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
329 |
203 |
$7K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
425 |
388 |
$7K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
318 |
292 |
$7K |
| 83605 |
|
1,694 |
1,328 |
$7K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,449 |
1,264 |
$6K |
| 85027 |
|
1,626 |
1,487 |
$6K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
187 |
174 |
$6K |
| 83880 |
|
616 |
519 |
$5K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,007 |
2,513 |
$5K |
| 83735 |
|
1,695 |
1,233 |
$5K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
77 |
70 |
$4K |
| 87186 |
|
863 |
741 |
$4K |
| 87077 |
|
884 |
772 |
$4K |
| 83690 |
|
1,513 |
1,297 |
$4K |
| 85610 |
|
1,907 |
1,499 |
$4K |
| 82607 |
|
346 |
325 |
$3K |
| 81003 |
|
2,467 |
2,182 |
$3K |
| 82248 |
|
1,538 |
1,308 |
$3K |
| 87040 |
|
492 |
331 |
$3K |
| 81001 |
|
1,656 |
1,436 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
413 |
370 |
$2K |
| 81025 |
|
322 |
287 |
$2K |
| 80050 |
General health panel |
55 |
52 |
$2K |
| 82803 |
|
311 |
242 |
$2K |
| 82550 |
|
769 |
645 |
$2K |
| 87081 |
|
563 |
504 |
$2K |
| 73630 |
|
156 |
130 |
$2K |
| 97161 |
|
30 |
26 |
$2K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
28 |
27 |
$1K |
| 85379 |
|
231 |
197 |
$1K |
| 73610 |
|
88 |
78 |
$1K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
22 |
22 |
$1K |
| 82043 |
|
323 |
292 |
$1K |
| 87088 |
|
180 |
162 |
$1K |
| 86140 |
|
401 |
343 |
$1K |
| 90746 |
|
14 |
12 |
$1K |
| 82570 |
|
252 |
225 |
$1K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
715 |
627 |
$950.52 |
| Q3014 |
Telehealth originating site facility fee |
45 |
32 |
$942.59 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
51 |
50 |
$896.51 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
65 |
61 |
$886.04 |
| 90656 |
|
67 |
66 |
$748.80 |
| 83540 |
|
187 |
170 |
$737.29 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
30 |
25 |
$727.30 |
| 84466 |
|
132 |
119 |
$662.50 |
| 84439 |
|
84 |
78 |
$658.91 |
| 86803 |
|
79 |
78 |
$650.62 |
| 82728 |
|
91 |
81 |
$570.16 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
99 |
85 |
$537.86 |
| 96376 |
|
56 |
38 |
$519.28 |
| 73030 |
|
59 |
52 |
$485.58 |
| 85007 |
|
147 |
136 |
$458.37 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,347 |
1,128 |
$431.12 |
| 84703 |
|
117 |
99 |
$417.20 |
| 72110 |
|
28 |
27 |
$405.06 |
| 80306 |
|
55 |
47 |
$396.72 |
| 84100 |
|
167 |
130 |
$358.82 |
| 90686 |
|
43 |
33 |
$351.82 |
| 84460 |
|
84 |
80 |
$334.12 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20 |
18 |
$332.08 |
| 82962 |
|
276 |
125 |
$317.13 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
12 |
12 |
$276.12 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14 |
14 |
$270.87 |
| 90715 |
|
16 |
13 |
$238.30 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
15 |
12 |
$235.58 |
| 85652 |
|
173 |
146 |
$234.01 |
| 84450 |
|
63 |
60 |
$222.30 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
13 |
13 |
$216.78 |
| 84153 |
|
16 |
15 |
$190.16 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
78 |
61 |
$183.49 |
| 73560 |
|
18 |
15 |
$179.64 |
| 73562 |
|
32 |
24 |
$173.66 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
135 |
100 |
$172.92 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,081 |
894 |
$170.01 |
| 87807 |
|
13 |
13 |
$160.24 |
| 74018 |
|
12 |
12 |
$147.68 |
| 80076 |
|
16 |
14 |
$111.78 |
| 82948 |
|
16 |
14 |
$90.14 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
129 |
121 |
$83.02 |
| 82746 |
|
14 |
13 |
$82.02 |
| C1755 |
Catheter, intraspinal |
14 |
12 |
$69.80 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
65 |
53 |
$62.63 |
| 96367 |
|
18 |
12 |
$61.82 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
94 |
76 |
$58.07 |
| 85730 |
|
14 |
13 |
$50.26 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
18 |
16 |
$46.46 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
34 |
29 |
$31.71 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
13 |
12 |
$5.28 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
44 |
32 |
$4.68 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
63 |
52 |
$1.00 |
| J3490 |
Unclassified drugs |
1,326 |
611 |
$0.00 |
| G0475 |
Hiv antigen/antibody, combination assay, screening |
13 |
13 |
$0.00 |